Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

Covington Advises Intercell in Acquisition of Iomai Corporation


WASHINGTON, DC, August 7, 2008 — On August 5, Intercell AG completed its acquisition of Iomai Corporation (now known as Intercell USA, Inc.) in a deal that will create a leading traveler’s vaccine portfolio. Covington & Burling LLP advised Intercell on the transaction.

Intercell is a growing biotechnology company which focuses on the design and development of novel vaccines for the prevention and treatment of infectious diseases with substantial unmet medical need. Iomai is a company that discovers and develops vaccines and immune system stimulants delivered via a novel, needle-free technology called transcutaneous immunization (TCI). The technology was discovered by researchers at the Walter Reed Army Institute of Research.

Leading the Covington team from the Washington and New York offices were corporate partners Catherine Dargan and Stephen Infante, and associates Scott Roades and Libby Speth. Also involved in the transaction were partner David Engvall and associate Keir Gumbs (securities); partner James Dean (antitrust); partner Mark Plotkin and associate David Fagan (CFIUS); partner Michael Francese and associates Mary DeYoung and Susannah Vance (benefits); of counsel Scott Schrader and associate Jessica Milner (IP); special counsel Jennifer Plitsch (Government contracts); and partner Robert Heller (tax).

Share this article: